Mesenchymal stem cell transplantation ameliorates motor function deterioration of spinocerebellar ataxia by rescuing cerebellar Purkinje cells

Journal of Biomedical Science

Volumn 18, Issue 1, 2011, Pages

  Chang, You Kang ^a,b,c   Chen, Ming Hsiang ^a   Chiang, Yi Hung ^a   Chen, Yu Fan ^a   Ma, Wei Hsien ^a   Tseng, Chian You ^a   Soong, Bin Wen ^a,d   Ho, Jennifer H ^e,f   Lee, Oscar K ^a,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 2; POLYGLUTAMINE; PROTEIN; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; FERRIC ION; FERRIC OXIDE; METAL NANOPARTICLE; NERVE PROTEIN; PEPTIDE; SCA2 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CELL SURVIVAL; CONTROLLED STUDY; FUNCTIONAL ASSESSMENT; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STEM CELL TRANSPLANTATION; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PURKINJE CELL; ROTAROD TEST; SPINOCEREBELLAR DEGENERATION; TREATMENT OUTCOME; ANALYSIS OF VARIANCE; ANIMAL; EVALUATION; GENETICS; MOTOR ACTIVITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALIA; MUS; MUS MUSCULUS;

ANALYSIS OF VARIANCE; ANIMALS; FERRIC COMPOUNDS; HUMANS; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MESENCHYMAL STEM CELL TRANSPLANTATION; METAL NANOPARTICLES; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; PEPTIDES; PURKINJE CELLS; ROTAROD PERFORMANCE TEST; SPINOCEREBELLAR ATAXIAS;

EID: 79961122734     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-18-54     Document Type: Article

References (35)

1. Classification of the hereditary ataxias and paraplegias. AE Harding, Lancet 1983 1 1151 1155 (Pubitemid 13084682)
2. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. A Durr, Lancet Neurol 2010 9 885 894 10.1016/S1474-4422(10)70183-6 20723845
3. Spinocerebellar ataxias: an update. BW Soong, HL Paulson, Curr Opin Neurol 2007 20 438 446 10.1097/WCO.0b013e3281fbd3dd 17620880 (Pubitemid 47051992)
4. Spinocerebellar ataxias caused by polyglutamine expansions: a review of therapeutic strategies. BR Underwood, DC Rubinsztein, Cerebellum 2008 7 215 221 10.1007/s12311-008-0026-z 18418676
5. CAG repeat disorder models and human neuropathology: similarities and differences. M Yamada, T Sato, S Tsuji, H Takahashi, Acta Neuropathol 2008 115 71 86 17786457 (Pubitemid 350238668)
6. Pathways to motor incoordination: the inherited ataxias. F Taroni, S DiDonato, Nat Rev Neurosci 2004 5 641 655 15263894 (Pubitemid 39013595)
7. Antisense RNA sequences modulating the ataxin-1 message: molecular model of gene therapy for spinocerebellar ataxia type 1, a dominant-acting unstable trinucleotide repeat disease. Y Gao, T Zu, WC Low, HT Orr, RS McIvor, Cell Transplant 2008 17 723 734 10.3727/096368908786516729 19044200
8. Spinocerebellar ataxia 2 (SCA2). I Lastres-Becker, U Rub, G Auburger, Cerebellum 2008 7 115 124 10.1007/s12311-008-0019-y 18418684
9. Cerebellar allografts survive and transiently alleviate ataxia in a transgenic model of spinocerebellar ataxia type-1. WF Kaemmerer, WC Low, Exp Neurol 1999 158 301 311 10.1006/exnr.1999.7099 10415138 (Pubitemid 29382822)
10. Grafting neural precursor cells promotes functional recovery in an SCA1 mouse model. S Chintawar, R Hourez, A Ravella, D Gall, D Orduz, M Rai, DP Bishop, S Geuna, SN Schiffmann, M Pandolfo, J Neurosci 2009 29 13126 13135 10.1523/JNEUROSCI.0647-09.2009 19846700
11. Mesenchymal stem cells rescue Purkinje cells and improve motor functions in a mouse model of cerebellar ataxia. J Jones, J Jaramillo-Merchan, C Bueno, D Pastor, M Viso-Leon, S Martinez, Neurobiol Dis 2010 40 415 423 10.1016/j.nbd.2010.07.001 20638477
12. Multilineage potential of adult human mesenchymal stem cells. MF Pittenger, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MA Moorman, DW Simonetti, S Craig, DR Marshak, Science 1999 284 143 147 10.1126/science.284. 5411.143 10102814 (Pubitemid 29282067)
13. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. OK Lee, TK Kuo, WM Chen, KD Lee, SL Hsieh, TH Chen, Blood 2004 103 1669 1675 10.1182/blood-2003-05-1670 14576065 (Pubitemid 38268958)
14. Stem cell characteristics of human trabecular bone-derived cells. V Sottile, C Halleux, F Bassilana, H Keller, K Seuwen, Bone 2002 30 699 704 10.1016/S8756-3282(02)00674-9 11996907 (Pubitemid 34467990)
15. Multipotent mesenchymal stem cells from adult human synovial membrane. C De Bari, F Dell'Accio, P Tylzanowski, FP Luyten, Arthritis Rheum 2001 44 1928 1942 10.1002/1529-0131(200108)44:8<1928::AID-ART331>3.0.CO;2-P 11508446 (Pubitemid 32758241)
16. Human adipose tissue is a source of multipotent stem cells. PA Zuk, M Zhu, P Ashjian, DA De Ugarte, JI Huang, H Mizuno, ZC Alfonso, JK Fraser, P Benhaim, MH Hedrick, Mol Biol Cell 2002 13 4279 4295 10.1091/mbc.E02-02-0105 12475952 (Pubitemid 35471185)
17. Infusion of allogeneic-related HLA mismatched mesenchymal stem cells for the treatment of incomplete engraftment following autologous haematopoietic stem cell transplantation. L Fouillard, A Chapel, D Bories, S Bouchet, JM Costa, H Rouard, P Herve, P Gourmelon, D Thierry, M Lopez, et al. Leukemia 2007 21 568 570 10.1038/sj.leu.2404550 17252011
18. Allogeneic bone marrow transplantation (BMT) for refractory Behcet's disease with severe CNS involvement. AM Marmont, F Gualandi, G Piaggio, M Podesta, M Teresa van Lint, A Bacigalupo, F Nobili, Bone Marrow Transplant 2006 37 1061 1063 10.1038/sj.bmt.1705372 16633360
19. Mesenchymal stem cells: mechanisms of immunomodulation and homing. H Yagi, A Soto-Gutierrez, B Parekkadan, Y Kitagawa, RG Tompkins, N Kobayashi, ML Yarmush, Cell Transplant 2010 19 667 679 10.3727/096368910X508762 20525442
20. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. PH Lee, JW Kim, OY Bang, YH Ahn, IS Joo, K Huh, Clin Pharmacol Ther 2008 83 723 730 10.1038/sj.clpt.6100386 17898702 (Pubitemid 351556019)
21. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease. NK Venkataramana, SK Kumar, S Balaraju, RC Radhakrishnan, A Bansal, A Dixit, DK Rao, M Das, M Jan, PK Gupta, et al. Transl Res 2010 155 62 70 10.1016/j.trsl.2009.07.006 20129486
22. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial. L Mazzini, I Ferrero, V Luparello, D Rustichelli, M Gunetti, K Mareschi, L Testa, A Stecco, R Tarletti, M Miglioretti, et al. Exp Neurol 2010 223 229 237 10.1016/j.expneurol.2009.08.007 19682989
23. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. JS Lee, JM Hong, GJ Moon, PH Lee, YH Ahn, OY Bang, Stem Cells 2010 28 1099 1106 10.1002/stem.430 20506226
24. In utero transplantation of human bone marrow-derived multipotent mesenchymal stem cells in mice. SH Chou, TK Kuo, M Liu, OK Lee, J Orthop Res 2006 24 301 312 10.1002/jor.20047 16482576 (Pubitemid 43772989)
25. In vitro hepatic differentiation of human mesenchymal stem cells. KD Lee, TK Kuo, J Whang-Peng, YF Chung, CT Lin, SH Chou, JR Chen, YP Chen, OK Lee, Hepatology 2004 40 1275 1284 10.1002/hep.20469 15562440 (Pubitemid 39657001)
26. Fluvastatin and lovastatin but not pravastatin induce neuroglial differentiation in human mesenchymal stem cells. OK Lee, YC Ko, TK Kuo, SH Chou, HJ Li, WM Chen, TH Chen, Y Su, J Cell Biochem 2004 93 917 928 10.1002/jcb.20241 15389871 (Pubitemid 44264147)
27. Aqueous dispersions of magnetite nanoparticles with NH3+ surfaces for magnetic manipulations of biomolecules and MRI contrast agents. DB Shieh, FY Cheng, CH Su, CS Yeh, MT Wu, YN Wu, CY Tsai, CL Wu, DH Chen, CH Chou, Biomaterials 2005 26 7183 7191 10.1016/j.biomaterials.2005.05.020 15964622 (Pubitemid 41095541)
28. Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. DP Huynh, K Figueroa, N Hoang, SM Pulst, Nat Genet 2000 26 44 50 10.1038/79162 10973246
29. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. RH Lee, AA Pulin, MJ Seo, DJ Kota, J Ylostalo, BL Larson, L Semprun-Prieto, P Delafontaine, DJ Prockop, Cell Stem Cell 2009 5 54 63 10.1016/j.stem.2009.05.003 19570514
30. Neuroprotective effect of human mesenchymal stem cells in an animal model of double toxin-induced multiple system atrophy-parkinsonism. HJ Park, G Bang, BR Lee, HO Kim, PH Lee, Cell Transplant 2010
31. Therapeutic Effects of Umbilical Cord Blood-Derived Mesenchymal Stem Cell Transplantation in Experimental Lupus Nephritis. JW Chang, SP Hung, HH Wu, WM Wu, AH Yang, HL Tsai, LY Yang, OK Lee, Cell Transplant 2011 20 245 257 10.3727/096368910X520056 20719085
32. Mesenchymal stem cells as therapeutics. B Parekkadan, JM Milwid, Annu Rev Biomed Eng 2010 12 87 117 10.1146/annurev-bioeng-070909-105309 20415588
33. Spinocerebellar ataxia 2 (SCA2): morphometric analyses in 11 autopsies. R Estrada, J Galarraga, G Orozco, A Nodarse, G Auburger, Acta Neuropathol 1999 97 306 310 10.1007/s004010050989 10090679 (Pubitemid 29137281)
34. Mesenchymal stem cell transplantation for neurodegenerative diseases. Y Torrente, E Polli, Cell Transplant 2008 17 1103 1113 10.3727/096368908787236576 19181205
35. Murine but not human mesenchymal stem cells generate osteosarcoma-like lesions in the lung. S Aguilar, E Nye, J Chan, M Loebinger, B Spencer-Dene, N Fisk, G Stamp, D Bonnet, SM Janes, Stem Cells 2007 25 1586 1594 10.1634/stemcells.2006-0762 17363552 (Pubitemid 47106029)